Aurobindo Pharma informs about completion of inspection

20 Sep 2023 Evaluate

 Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that the United States Food and Drug Administration (US FDA) inspected the Unit IV, a Formulation manufacturing facility, of APL Healthcare, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023. At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature. The company will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest. 

The above information is a part of company’s filings submitted to BSE.


Aurobindo Pharma Share Price

1223.65 3.45 (0.28%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.